Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports Medicine For Flu involves 8 relevant journals , 5 upcoming Conference, 1 socities, 15 Collaboration, 35 Media Partners and 818 National symposiums are presently dedicated exclusively to Flu Medicines and about 1,633 open access articles and 5,465 Conference Proceedings are being published on Medicine For Flu.
Flu symptoms and treatment involves vaccines and antiviral drugs. The flu is linked to between 3,000 and 49,000 deaths and 200,000 hospitalizations each year in the United States. The seasonal flu vaccine was created to try to avert these epidemics. There are three FDA-approved influenza antiviral drugs recommended by CDC this season to treat influenza. The brand names for these are Tamiflu® (generic name oseltamivir), Relenza® (generic name zanamivir), and Rapivab® (generic name peramivir).
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
The Medicine For Flu conference are set to cover various perception of researches involved with flu and control measures. This would help to accommodate every possible researchers working on flu to help build a vivid picture about this common infectious disease. We will have speakers, poster sessions and workshops designed to represent the talks from experts and students. From its seasonal occurrence to global challenges the threat of influenza spread has jeopardized most of our normal life. Researches are along the way for an effective and potent vaccination which is yet to realize its fullest goal. The researchers from Virology, Microbiology, Public health, Immunologists, Physicians, NHS and healthcare will be available to exchange their thoughts and clinical outcomes on treating flu and related variants.
Treatments for influenza include a range of medications and therapies that are used in response to disease influenza. Treatments may either directly target the influenza virus itself; or instead they may just offer relief to symptoms of the disease, while the body's own immune system works to recover from infection.The two main classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as zanamivir and oseltamivir, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. These drugs can reduce the severity of symptoms if taken soon after infection and can also be taken to decrease the risk of infection. However, virus strains have emerged that show drug resistance to both classes of drug.
Influenza viruses can show resistance to anti-viral drugs. Like the development of bacterial antibiotic resistance, this can result from over-use of these drugs. For example, a recent study published in the June 2009 Issue of Nature Biotechnology emphasized the urgent need for augmentation of oseltamivir (Tami-flu) stockpiles with additional antiviral drugs including zanamivir (Relenza) based on an evaluation of the performance of these drugs in the scenario that the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the tamiflu-resistance (His274Tyr) mutation which is currently widespread in seasonal H1N1 strains. Yet another example is in the case of the amantadines treatment may lead to the rapid production of resistant viruses, and over-use of these drugs has probably contributed to the spread of resistance.In particular, this high-level of resistance may be due to the easy availability of amantadines as part of over-the-counter cold remedies in countries such as China and Russia, and their use to prevent outbreaks of influenza in farmed poultry.On the other hand, a few strains resistant to neuraminidase inhibitors have emerged and circulated in the absence of much use of the drugs involved, and the frequency with which drug resistant strains appears shows little correlation with the level of use of these drugs. However, laboratory studies have shown that it is possible for the use of sub-optimal doses of these drugs as a prophylactic measure might contribute to the development of drug resistance. During the United States 2005–2006 influenza season, increasing incidence of drug resistance by strain H3N2 to amantadine and rimantadine led the CDC to recommend oseltamivir as a prophylactic drug, and the use of either oseltamivir or zanamivir as treatment.
Market Analysis:
The market of Flu consists of products to prevent, treat, and diagnose influenza viruses during both seasonal and pandemic episodes. Also included in the market is the stockpiling efforts and spending on new vaccine/therapeutic contracts. The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Global influenza market to be worth $6.3 billion in 2014 for a compound annual growth rate (CAGR) of 2.7%.This year, the global market for products used in the fight against influenza will be worth an estimated $5.5 billion, according to a new technical market research report, the Global Influenza Market, from BCC Research.
International symposium and workshops
29th International Conference on Antiviral Research (ICAR), April 17-21, 2016, USA.
British Infection Association's 9th HIV Dilemmas Meeting, January 29 2016, UK.
5th Eastern Europe and Central Asia AIDS Conference, March 23-25, 2016, Russia.
List of Best International Conferences:
2nd Flu Conference
November 17-19, 2016 San Francisco, USA.
4th Bacteriology and Infectious Diseases Congress
May 16-18, 2016 San Antonio, USA.
2nd Influenza Conferences
September 12-14, 2016 Berlin, Germany.
H1N1 & Influenza Vaccines Conference
July 18-20, 2016 Chicago, USA.
2nd Infectious Diseases Congress,
August 25-27, 2016 Philadelphia, USA.
2nd Parasitology Conferences,
August 01-03, 2016 Manchester, UK.
Trauma & Critical Care Congress
March 07-09, 2016 Madrid, Spain.
4th Immunology Conference
October 24-26, 2016, Chicago, USA.
11th Vaccines & Vaccination Summit
September 12-14, 2016, Pheonix, USA.
7th Middle East Vaccines & Vaccination Summit
September 28-30, 2015 at Dubai, UAE.
4th Lung & Respiratory Care Conference
August 01-03, 2016 Manchester, UK.
13th Asia Pacific Vaccines & Vaccination Summit
November 10-12, 2016 Melbourne, Australia.
Infection Prevention and Control Conferences
August 1-2, 2016 Frankfurt, Germany.
European Infectious Diseases Conference,
August 1-3, 2016 Frankfurt, Germany.
Tarvel Medicine and Vaccines Conferences
August 1-2, 2016 Seattle, USA.
2nd Respiratory and Pulmonary Medicine Conference
May 09-10, 2016 Chicago, USA.
Children Vaccines Congress,
October 10-12, 2016 Kuala Lumpur, Malaysia.
2nd Retroviruses and Novel Drugs Conferences
June 30-July 1, 2016 Capetown, South Africa.
4th Epidemiology and Public Health Conference
October 03-05, 2016 London, UK.
5th Occupational Health & Safety Conference
June 06-07, 2016 Dallas, USA.
Relevant Society and Associations:
Companies
This page will be updated regularly.
This page was last updated on November 5, 2024
